Acumen Pharmaceuticals (ABOS) Net Equity Issued and Repurchased (2021 - 2024)

Acumen Pharmaceuticals (ABOS) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $7.9 million in Q1 2024.

• For the quarter ending Q1 2024, Net Equity Issued and Repurchased changed N/A year-over-year to $7.9 million; the trailing twelve-month figure through Dec 2024 stood at $7.9 million (down 93.49% YoY), and the FY2024 full-year result was $7.9 million, down 93.49% from the prior year.
• Net Equity Issued and Repurchased climbed to $7.9 million in Q1 2024, from -$390000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $138.5 million in Q3 2021 to a low of -$390000.0 in Q4 2023.
• A 4-year average of $45.4 million and a median of $5.9 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased jumped 126500.0% in 2022 and plunged 110.28% in 2023, its largest moves.
• Tracing ABOS's Net Equity Issued and Repurchased over 4 years: stood at -$3000.0 in 2021, then jumped by 126500.0% to $3.8 million in 2022, then plunged by 110.28% to -$390000.0 in 2023, then surged by 2135.38% to $7.9 million in 2024.
• Business Quant data shows ABOS's Net Equity Issued and Repurchased at $7.9 million in Q1 2024, -$390000.0 in Q4 2023, and $122.3 million in Q3 2023.